SOURCE: Hamilton Thorne

Hamilton Thorne

April 06, 2015 16:20 ET

Hamilton Thorne Announces Availability of Oosight® Product Line

BEVERLY, MA and TORONTO, ON--(Marketwired - Apr 6, 2015) - Hamilton Thorne Ltd. (TSX VENTURE: HTL), a leading provider of precision laser devices and advanced image analysis systems for the fertility, stem cell and developmental biology research markets, today announced that the Company now offers the Oosight® product line, which it has acquired from Cambridge Research & Instrumentation, Inc. (CRi). 

"The Oosight system is a unique instrument that is complementary to our laser products in both fertility and developmental biology research labs," remarked David Wolf, President and CEO of Hamilton Thorne. "As a long-term distributor of the Oosight system we have already completed the technical integration of the Oosight with our laser products. We believe that by leveraging our established, world-wide sales channels and investing in product marketing, we can generate incremental sales of the Oosight product."

The Oosight system provides high-contrast live images of unfertilized eggs (oocytes),capturing quantitative data of important structures using a patented non-invasive, polarized-light technique developed by the Marine Biological Laboratory and commercialized by CRi as LC-PolScope™ technology. The Oosight system's visualization capabilities have enabled breakthroughs in assisted reproductive technology, stem cell generation and developmental biology research.

Additional information on the Oosight product and its multiple applications can be found at www.hamiltonthorne.com/index.php/oosight-overview.

Financial terms of the transaction were not disclosed.

About Hamilton Thorne Ltd. (www.hamiltonthorne.com)
Hamilton Thorne designs, manufactures and distributes precision laser devices and advanced imaging systems for the fertility, stem cell and developmental biology research markets. It provides novel solutions for Life Science that reduce cost, increase productivity, improve results and enable research breakthroughs in fertility, regenerative medicine, and stem cell research markets. Hamilton Thorne's laser products attach to standard inverted microscopes and operate as robotic micro-surgeons, enabling a wide array of scientific applications and IVF procedures. Its imaging systems improve outcomes in human IVF clinics and animal breeding facilities and provide high-end toxicology analyses. 

Hamilton Thorne's growing customer base includes pharmaceutical companies, biotechnology companies, fertility clinics, university research centers, and other commercial and academic research establishments worldwide. Current customers include world-leading research labs such as Harvard, MIT, Yale, McGill, DuPont, Monsanto, Charles River Labs, Jackson Labs, Merck, Novartis, Pfizer, and Oxford and Cambridge.

Neither the Toronto Venture Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release.

Certain information in this press release may contain forward-looking statements. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements unless and until required by securities laws applicable to the Company. Additional information identifying risks and uncertainties is contained in filings by the Company with the Canadian securities regulators, which filings are available at www.sedar.com.

Contact Information

  • For more information, please contact:

    David Wolf
    President & CEO
    Hamilton Thorne Ltd.
    978-921-2050
    Email Contact

    Michael Bruns
    CFO
    Hamilton Thorne Ltd.
    978-921-2050
    Email Contact